Clinical Trial

Clinical Study on the Efficacy and Safety of CAR-DC in the Treatment of Advanced Solid Tumors

Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This is a prospective, open label, single arm clinical trial to evaluate the safety and the preliminary efficacy of chimeric antigen receptor-dendritic cell (CAR-DC) in the treatment of advanced solid tumors positive for one of the following antigens: ephrin type-A receptor 2 (EphA2), claudin-18 isoform 2 (CLDN18.2) , trophoblast cell surface antigen 2 (Trop2), human epidermal growth factor receptor 2 (HER2), guanylyl cyclase-C (GCC), glypican-3 (GPC3) and carcinoembryonic antigen (CEA).
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Not Yet Recruiting 2026-06-04
Trial Details
NCT Number NCT07504445
Lead Sponsor Peking University Shenzhen Hospital
Conditions Advanced Solid Tumors
Enrollment 10 participants
Start Date 2026-06-10
Primary Completion 2028-04-03 (estimated)
Study Completion 2028-04-03 (estimated)
Updated on ClinicalTrials.gov 2026-06-03